For more than 40 years, beta blockers have been one of the most common medicines given to people after a heart attack.
Doctors around the world have long believed these drugs help protect the heart and reduce the risk of future problems.
But a major new international study is now challenging that long-standing practice.
Researchers say that many patients who recover from an uncomplicated heart attack and still have normal heart function may not benefit from beta blockers at all. The findings could eventually change treatment guidelines worldwide and reduce the number of medications many heart patients take.
The study was called the REBOOT Trial and was led by Dr. Valentin Fuster of Mount Sinai Fuster Heart Hospital and Spain’s Centro Nacional de Investigaciones Cardiovasculares. The results were presented at the European Society of Cardiology Congress in Madrid and published in The New England Journal of Medicine.
A heart attack, also known as myocardial infarction, happens when blood flow to part of the heart becomes blocked. Without oxygen-rich blood, heart muscle can become damaged or die.
Decades ago, heart attack treatment was very different from today. Blocked arteries often stayed closed for longer periods, and doctors had fewer tools to prevent complications.
At that time, beta blockers became a standard treatment because they helped slow the heart rate, lower blood pressure, reduce the heart’s oxygen demand, and lower the risk of dangerous heart rhythm problems.
Over the years, beta blockers became routine for most heart attack patients.
However, modern heart care has improved dramatically. Today, doctors can often reopen blocked arteries quickly using procedures such as angioplasty and stents. Patients also receive powerful modern treatments including statins, antiplatelet drugs, and other medications that lower cardiovascular risk.
Because of these advances, researchers began asking an important question: do beta blockers still provide extra protection for patients whose heart function remains normal after a heart attack?
The REBOOT Trial was designed to answer that question directly.
The study included 8,505 patients from 109 hospitals in Spain and Italy. All participants had experienced an uncomplicated heart attack and still had preserved heart function, meaning their hearts were pumping blood normally.
After leaving the hospital, patients were randomly assigned either to receive beta blockers or not receive them. Researchers then followed the participants for nearly four years on average.
The results surprised many experts.
The study found that beta blockers did not significantly reduce the risk of death, repeat heart attack, or hospitalization for heart failure in these patients.
This finding is important because more than 80 percent of patients with uncomplicated heart attacks are currently prescribed beta blockers after leaving the hospital.
Researchers say that if many patients are not benefiting from the drugs, doctors may eventually reduce unnecessary prescribing. This could simplify recovery plans and reduce medication side effects.
Although beta blockers are generally considered safe, they can cause problems such as fatigue, dizziness, low heart rate, and sexual dysfunction. Some patients also find it difficult to manage multiple medications after a heart attack.
The study also raised another important issue involving women.
A separate REBOOT analysis published in the European Heart Journal found that women who received beta blockers after uncomplicated heart attacks had a higher risk of death, another heart attack, or hospitalization for heart failure compared with women who did not receive the drugs.
This increased risk was especially noticeable in women whose heart function was completely normal.
Researchers stressed that the findings do not mean patients should suddenly stop taking prescribed beta blockers on their own. Instead, the results suggest doctors may need to make more personalized decisions based on each patient’s condition.
The findings are also part of a larger shift happening in modern medicine. Researchers are increasingly questioning whether older treatments developed decades ago still provide the same benefits in the era of advanced medical care.
Other recent studies have produced similar results. The REDUCE-AMI trial in 2024 also found no major benefit from beta blockers in certain heart attack patients with normal heart function.
However, not all studies fully agree. Some research suggests patients with mildly reduced heart function may still benefit from beta blockers.
Scientists say this means beta blockers are still important for many people, especially those with weaker heart function or other heart conditions. But routine use in all heart attack patients may no longer make sense.
Looking at the findings overall, the REBOOT Trial appears highly influential because it involved a very large number of patients and was carefully designed. The study strongly challenges a treatment practice that has existed for decades.
At the same time, the findings also highlight the growing importance of personalized medicine, where treatments are adjusted to fit individual patient needs rather than applied universally.
More research will still be needed to refine treatment recommendations, especially for women and patients with mildly reduced heart function.
However, the study may eventually lead to major changes in heart attack care, helping some patients avoid unnecessary medications and side effects while still receiving the treatments that matter most.
Source: Mount Sinai Fuster Heart Hospital and CNIC.
